Share on StockTwits
 

Sinclair IS Pharma Plc (LON:SPH)‘s stock had its “buy” rating reaffirmed by equities research analysts at FinnCap in a research note issued to investors on Friday, American Banking News reports. They currently have a GBX 48 ($0.79) price objective on the stock. FinnCap’s price target points to a potential upside of 51.18% from the company’s current price.

Sinclair IS Pharma Plc (LON:SPH) opened at 31.75 on Friday. Sinclair IS Pharma Plc has a 52 week low of GBX 23.15 and a 52 week high of GBX 34.00. The stock has a 50-day moving average of GBX 30.3 and a 200-day moving average of GBX 29.08.

SPH has been the subject of a number of other recent research reports. Analysts at Jefferies Group raised their price target on shares of Sinclair IS Pharma Plc from GBX 48 ($0.79) to GBX 50 ($0.82) in a research note to investors on Tuesday, January 21st. They now have a “buy” rating on the stock. Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Sinclair IS Pharma Plc in a research note to investors on Thursday, January 16th. They now have a GBX 38 ($0.63) price target on the stock. Finally, analysts at Investec cut their price target on shares of Sinclair IS Pharma Plc from GBX 38 ($0.63) to GBX 36 ($0.59) in a research note to investors on Thursday, January 16th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of GBX 67.66 ($1.11).

Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.